Welcome to our dedicated page for GBT news (Ticker: GBT), a resource for investors and traders seeking the latest updates and insights on GBT stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GBT's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GBT's position in the market.
Global Blood Therapeutics (GBT) will report its third quarter 2021 financial results on November 4, 2021, after market close, followed by a conference call at 4:30 p.m. ET. The company will also host an R&D Day on November 11, 2021, in New York City, discussing its product Oxbryta® and pipeline developments including inclacumab and GBT021601. GBT aims to improve treatments for sickle cell disease (SCD), continuing its commitment to underserved patient communities.
Global Blood Therapeutics (GBT) announced the grant of 22 new employees restricted stock units totaling 54,750 shares under the Amended and Restated 2017 Inducement Equity Plan. The awards were issued on October 1, 2021, as an inducement for new hires, in compliance with NASDAQ Listing Rule 5635(c)(4). GBT aims to transform sickle cell disease treatment, with products including Oxbryta and ongoing development projects like inclacumab and GBT021601. The company is committed to advancing its pipeline for underserved patient communities.
Global Blood Therapeutics, Inc. (GBT) announced its participation in a virtual fireside chat at the Cantor Global Healthcare Conference on September 27, 2021, at 2:40 p.m. ET. The chat will be available to stream live on GBT's website, with an archived replay accessible for a month after the event. GBT focuses on developing treatments for sickle cell disease (SCD), having launched its first FDA-approved treatment, Oxbryta, and advancing its pipeline with inclacumab and GBT021601 for SCD. For more information, visit www.gbt.com.
Global Blood Therapeutics (GBT) announced the launch of The GBT Foundation on September 14, 2021, a 501(c)(3) nonprofit aimed at improving health equity for underserved communities, particularly those affected by sickle cell disease (SCD). The foundation will focus on increasing education, empowering individuals, enhancing healthcare access, and promoting health equity. Currently accepting grant proposals, it aims to fund programs that create sustainable changes. The GBT Foundation aligns with GBT’s mission to transform care for SCD through community-focused initiatives.
Global Blood Therapeutics (GBT) announced on September 1, 2021, that it granted stock options and restricted stock units to 20 new employees. The aggregate award included options to purchase 49,600 shares at an exercise price of $29.85 and 79,910 shares in restricted stock units under the Amended and Restated 2017 Inducement Equity Plan. These awards were made in accordance with NASDAQ Listing Rule 5635(c)(4) to attract new talent into the company, emphasizing GBT's commitment to enriching its workforce and advancing treatments for sickle cell disease.
Global Blood Therapeutics (GBT) will host the 10th Annual Sickle Cell Disease Therapeutics Conference on September 15th, featuring a keynote by Chiquita Brooks-LaSure, CMS Administrator. The virtual event coincides with National Sickle Cell Awareness Month. The conference will address the challenges faced by the SCD community, especially exacerbated by COVID-19. Experts will discuss treatment advancements and healthcare access, with participation from key industry players.
Global Blood Therapeutics (GBT) announced the FDA's acceptance of its supplemental New Drug Application for Oxbryta (voxelotor) targeting sickle cell disease (SCD) in children ages 4 to 11. The FDA has granted Priority Review, aiming for a decision by December 25, 2021. Oxbryta, currently available for patients 12 and older, shows promising results in a Phase 2a study, demonstrating improvements in hemoglobin and reduced hemolysis in pediatric patients. The dispersible tablet form, flavored for ease of use, fulfills a critical need in the treatment of SCD in younger populations.
Global Blood Therapeutics (GBT), based in South San Francisco, will participate in two virtual investor conferences. The 2021 Wells Fargo Virtual Healthcare Conference is scheduled for September 10 at 1:20 p.m. ET, followed by the Morgan Stanley 19th Annual Global Healthcare Conference on September 13 at 12:30 p.m. ET. These presentations will be available via a live webcast on GBT's website, with replays accessible for a month post-event. GBT is focused on transformative treatments for sickle cell disease, including its FDA-approved therapy, Oxbryta.
Global Blood Therapeutics (GBT) announced the grant of 33,050 restricted stock units to 12 new employees on August 1, 2021. This issuance was made under the Amended and Restated 2017 Inducement Equity Plan as an inducement for joining the company, in compliance with NASDAQ Listing Rule 5635(c)(4). GBT is focused on innovative treatments for sickle cell disease, including Oxbryta®, the first FDA-approved treatment targeting sickle hemoglobin polymerization, along with ongoing development of other promising therapies.
Global Blood Therapeutics (GBT) announced its participation in a virtual fireside chat at the Wedbush PacGrow Healthcare Conference on August 11, 2021, at 2:20 p.m. ET. The event will be streamed live on GBT’s website, with an archived replay available for a month.
GBT focuses on developing treatments for sickle cell disease (SCD), including the FDA-approved Oxbryta® and other promising pipeline programs like inclacumab and GBT021601.
FAQ
What is the market cap of GBT (GBT)?
